Coherus at Morgan Stanley healthcare conference: oncology push gains traction
On Wednesday, September 16, 2026, Coherus BioPharma, Inc. (CHRS) presented its strategic plans at the Morgan Stanley 24th Annual Global Healthcare Conference. The company is focusing on one approved drug and two experimental cancer programs to achieve self-funding and overcome biotech risks. LOQTORZI, a PD-1 therapy for nasopharyngeal cancer, is its main revenue driver and could surpass $30 million in quarterly sales later this year.
Tagmokitug and Casdozokitug are two experimental cancer programs developed with a biology-driven approach to counter immune resistance in various tumors. After cutting headcount to around 140 employees from about 360, Coherus now has a leaner structure. The company expects LOQTORZI to help it achieve SG&A breakeven by the end of 2027, reducing the need for additional capital raises.
LOQTORZI, Coherus' approved PD-1 inhibitor, is currently the only approved and available therapy in the U.S. for nasopharyngeal cancer, providing the company with a strategic advantage in clinical development and allowing them to explore more combination studies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
